has announced their latest pipeline analysis report on the JAK
inhibitors for lung cancer market. The report includes a
detailed analysis of the pipeline molecules under investigation within
the defined data collection period to treat eosinophilic esophagitis.
This press release features multimedia. View the full release here:
Technavio has published a new report on the drug development pipeline for JAK inhibitors for lung cancer, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including
regulatory framework, drug development strategies, recruitment
strategies, and key companies that are expected to play an essential
role in the growth of the market during the forecast period.
This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing
JAK inhibitors for lung cancer: Market overview
According to Center for Disease Control (CDC), lung cancer is one of the
leading causes of cancer mortality and the second most diagnosed cancer
for both men and women in the US. In lung cancer, cancer cells start
growing uncontrollably and may even start to spread to the lymph nodes
and other parts of the body. Similarly, cancer cells initiated in other
parts of the body may also spread to the lungs.
Lung cancer can be classified into two types which are small lung cancer
and NSCLC. The activation of Janus Kinase 1 is believed to play a
crucial role in the development of oncologic and autoimmune diseases.
JAK inhibitors are being developed for treatment of lung cancer.
According to a senior analyst at Technavio for research on infectious
and rare diseases, “In the current drug development pipeline, around
67% of the molecules under development are being developed by companies
in collaboration with institutions under a partnership program. For
instance, INCB39110 is under development by Incyte, AstraZeneca, and the
Trustees of the University of Pennsylvania.”
JAK inhibitors for lung cancer: Market
This market research report segments the JAK inhibitors for lung cancer
market based on drugs under development (preclinical, Phase I/II),
therapies employed (combination therapy, and monotherapy + combination
therapy), RoA (oral and unknown), therapeutic modality (small molecules,
and unknown), and geographical coverage. It provides an in-depth
analysis of the prominent factors influencing the market, including
drivers, opportunities, trends, and industry-specific challenges.
Monotherapy includes the use of a single drug to treat a disorder, while
combination therapy involves the use of more than one drug to treat a
disorder. In the current pipeline, a single molecule that is being
investigated is used as both monotherapy and combination therapy. With
respect to RoA, nearly 67% of the total therapeutics being developed are
for oral administration whereby the drug is administered through the
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
Drug Development Strategies
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005567/en/